stockportfolio.pro
Stocks / ENOV vs PAHC
ENOV vs PAHC
Enovis Corporation and Phibro Animal Health Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Enovis Corporation (ENOV) | Phibro Animal Health Corporation (PAHC) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $2.25B | $1.30B |
| Net income (latest FY) | $-1.18B | $48.30M |
| Revenue growth (5y CAGR) | 14.9% | 10.1% |
| Net margin | -52.7% | 3.7% |
| Return on equity | -79.5% | 16.9% |
| P/E ratio | — | 13.6 |
| Dividend yield | — | 1.5% |
| Profitable years (of last 10) | 5 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ENOV — free Open PAHC — freeFrequently asked questions
Which is bigger, ENOV or PAHC?
Phibro Animal Health Corporation is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, ENOV or PAHC?
Over the last five fiscal years, Enovis Corporation grew revenue faster — 14.9%/yr versus 10.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.